PUMA BIOTECHNOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $4.37 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $4.37, a 124.10% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $1.95, a 57.33% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $4.57, a 44.16% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $3.17, a 93.29% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.95, a 57.33% decline from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $4.57, a 44.16% increase from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.17, a 84.30% increase from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.72, a 78.23% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.37 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $4.37 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $1.95 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $1.95 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $1.95 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $1.95 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $4.57 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $4.57 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $4.57 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $4.57 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $3.17 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $3.17 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $3.17 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $3.17 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $1.72 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $1.72 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | $1.64 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $1.64 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $7.90 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $7.90 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $8.32 10-Q · filed 2021-08-05 | $8.32 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $8.54 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $7.81 10-K · filed 2023-03-02 | |||
| 2020-09-30 | $7.81 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $7.86 10-Q · filed 2021-08-05 | $7.86 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | $7.86 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $12.08 10-K · filed 2022-03-03 | |||
| 2019-09-30 | $21.82 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $21.82 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $21.82 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $45.62 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $56.46 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $56.46 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | $56.46 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $24.30 10-K · filed 2020-02-28 | |||
| 2017-09-30 | $24.30 10-Q · filed 2018-11-05 | |||
| 2017-06-30 | $24.30 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | $22.86 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $25.69 10-K · filed 2019-03-01 | |||
| 2016-09-30 | $26.79 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | $27.42 10-Q · filed 2017-08-09 | |||
| 2016-03-31 | $36.28 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | $68.30 10-K · filed 2018-03-09 | |||
| 2015-09-30 | $89.17 10-Q · filed 2016-11-09 | |||
| 2015-06-30 | $115.49 10-Q · filed 2016-08-09 | |||
| 2015-03-31 | $125.41 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $101.17 10-K · filed 2017-03-01 | |||
| 2014-09-30 | $86.83 10-Q · filed 2015-11-09 | |||
| 2014-06-30 | $65.85 10-Q · filed 2015-08-10 | |||
| 2014-03-31 | $73.89 10-Q · filed 2015-05-11 | $73.89 10-Q · filed 2014-05-12 | ||
| 2013-12-31 | $29.94 10-K · filed 2016-02-29 | |||
| 2013-09-30 | $25.95 10-Q · filed 2014-11-10 | |||
| 2013-06-30 | $20.55 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | $18.84 10-Q · filed 2013-05-09 | $18.84 10-Q · filed 2014-05-12 | ||
| 2012-12-31 | $6.38 10-K · filed 2015-03-02 | |||
| 2012-09-30 | $9.41 10-Q · filed 2012-11-14 | $4.63 10-Q · filed 2013-11-12 | ||
| 2012-06-30 | $7.59 10-Q · filed 2012-08-14 | $4.30 10-Q · filed 2013-08-06 | ||
| 2012-03-31 | $2.66 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | $2.66 10-K · filed 2013-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |